Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring

J. Romano; B. Variano; P. Coplan; J. Van Roey; K. Douville; Z. Rosenberg; M. Temmerman; H. Verstraelen; L. Van Bortel; S. Weyers; M. Mitchnick

doi:10.1089/aid.2008.0184

Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring

J. Romano, B. Variano, P. Coplan, J. Van Roey, K. Douville, Z. Rosenberg, M. Temmerman, H. Verstraelen, L. Van Bortel, S. Weyers, M. Mitchnick

Research output: Contribution to journal › Article › peer-review

128 Citations (Scopus)

Abstract

Vaginal delivery of 200mg or 25mg dapivirine from intravaginal rings (IVRs) was evaluated over a 7-day period in two phase 1 safety trials (IPM001 and IPM008, respectively) in a total of 25 healthy women 19 to 46 years of age. The IVR was generally safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups. Across both studies, dapivirine concentrations in vaginal fluids measured at the introitus, cervix, and ring area were within the mean range of 0.7-7.1μg/ml. Mean dapivirine concentrations in vaginal and cervical tissues on day 7 were 0.3-0.7μg/g in IPM001 and 1.5-3.5μg/g in IPM008. Mean plasma concentrations of dapivirine were <50pg/ml. Dapivirine from both IVRs was successfully distributed throughout the lower genital tract at concentrations >1000× the EC ₅₀ against wild-type HIV-1 (LAI) in MT4 cells suggesting that IVR delivery of microbicides is a viable option meriting further study.

Original language	English
Pages (from-to)	483-488
Number of pages	6
Journal	AIDS Research and Human Retroviruses
Volume	25
Issue number	5
DOIs	https://doi.org/10.1089/aid.2008.0184
Publication status	Published - 1 May 2009
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/aid.2008.0184

Cite this

@article{7bbe7fb64ada47588aeead973a5568e4,

title = "Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring",

abstract = "Vaginal delivery of 200mg or 25mg dapivirine from intravaginal rings (IVRs) was evaluated over a 7-day period in two phase 1 safety trials (IPM001 and IPM008, respectively) in a total of 25 healthy women 19 to 46 years of age. The IVR was generally safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups. Across both studies, dapivirine concentrations in vaginal fluids measured at the introitus, cervix, and ring area were within the mean range of 0.7-7.1μg/ml. Mean dapivirine concentrations in vaginal and cervical tissues on day 7 were 0.3-0.7μg/g in IPM001 and 1.5-3.5μg/g in IPM008. Mean plasma concentrations of dapivirine were <50pg/ml. Dapivirine from both IVRs was successfully distributed throughout the lower genital tract at concentrations >1000× the EC 50 against wild-type HIV-1 (LAI) in MT4 cells suggesting that IVR delivery of microbicides is a viable option meriting further study.",

author = "J. Romano and B. Variano and P. Coplan and {Van Roey}, J. and K. Douville and Z. Rosenberg and M. Temmerman and H. Verstraelen and {Van Bortel}, L. and S. Weyers and M. Mitchnick",

year = "2009",

month = may,

day = "1",

doi = "10.1089/aid.2008.0184",

language = "English",

volume = "25",

pages = "483--488",

journal = "AIDS Research and Human Retroviruses",

issn = "0889-2229",

publisher = "Mary Ann Liebert Inc.",

number = "5",

}

TY - JOUR

T1 - Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring

AU - Romano, J.

AU - Variano, B.

AU - Coplan, P.

AU - Van Roey, J.

AU - Douville, K.

AU - Rosenberg, Z.

AU - Temmerman, M.

AU - Verstraelen, H.

AU - Van Bortel, L.

AU - Weyers, S.

AU - Mitchnick, M.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Vaginal delivery of 200mg or 25mg dapivirine from intravaginal rings (IVRs) was evaluated over a 7-day period in two phase 1 safety trials (IPM001 and IPM008, respectively) in a total of 25 healthy women 19 to 46 years of age. The IVR was generally safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups. Across both studies, dapivirine concentrations in vaginal fluids measured at the introitus, cervix, and ring area were within the mean range of 0.7-7.1μg/ml. Mean dapivirine concentrations in vaginal and cervical tissues on day 7 were 0.3-0.7μg/g in IPM001 and 1.5-3.5μg/g in IPM008. Mean plasma concentrations of dapivirine were <50pg/ml. Dapivirine from both IVRs was successfully distributed throughout the lower genital tract at concentrations >1000× the EC 50 against wild-type HIV-1 (LAI) in MT4 cells suggesting that IVR delivery of microbicides is a viable option meriting further study.

AB - Vaginal delivery of 200mg or 25mg dapivirine from intravaginal rings (IVRs) was evaluated over a 7-day period in two phase 1 safety trials (IPM001 and IPM008, respectively) in a total of 25 healthy women 19 to 46 years of age. The IVR was generally safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups. Across both studies, dapivirine concentrations in vaginal fluids measured at the introitus, cervix, and ring area were within the mean range of 0.7-7.1μg/ml. Mean dapivirine concentrations in vaginal and cervical tissues on day 7 were 0.3-0.7μg/g in IPM001 and 1.5-3.5μg/g in IPM008. Mean plasma concentrations of dapivirine were <50pg/ml. Dapivirine from both IVRs was successfully distributed throughout the lower genital tract at concentrations >1000× the EC 50 against wild-type HIV-1 (LAI) in MT4 cells suggesting that IVR delivery of microbicides is a viable option meriting further study.

UR - http://www.scopus.com/inward/record.url?scp=66149175684&partnerID=8YFLogxK

U2 - 10.1089/aid.2008.0184

DO - 10.1089/aid.2008.0184

M3 - Article

C2 - 19388819

AN - SCOPUS:66149175684

SN - 0889-2229

VL - 25

SP - 483

EP - 488

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

IS - 5

ER -

Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this